Title: Unravelling the role of beta-CGRP in inflammatory bowel disease and its potential role
in gastrointestinal homeostasis
Version: 1 Date: 29 May 2024
Reviewer's report:
This is an observational study dealing with the circulating levels of beta calcitonin gene-
related peptide (beta-CGRP) measured by ELISA in patients with IBD in comparison with
healthy controls (HC) and chronic migraine (CM) patients. Although the results showed that
the circulating levels of beta-CGRP in both ulcerative colitis (UC) and Crohn's disease (CD)
patients were significantly lower than those in HC and CM it is neither logical nor reasonable to
reach such conclusions that beta-CGRP has a pathophysiological and protective role in patients
with IBD because this study did not perform any experiments regarding the pathophysiological
and protective role of this neuropeptide.  Apart from this, in the patients cohort, there were 5
CD patients with B2 or B3 and 5 with perianal diseases which cannot be regarded as the first
or initial stages of the disease, therefore,  it is also not appropriate to argue that "this reduction
is not secondary to an established chronic damage of the mucosa, but that could have a key
role in the maintenance of wall homeostasis in the initial IBD stages". However, to observe the
circulating levels of beta-CGRP is a good start to study its role in patients with IBD in terms of
biomarkers or therapeutic target in future.
Title: Unravelling the role of beta-CGRP in inflammatory bowel disease and its potential role
in gastrointestinal homeostasis
Version: 1 Date: 29 May 2024
Reviewer's report:
This is an observational study dealing with the circulating levels of beta calcitonin gene-
related peptide (beta-CGRP) measured by ELISA in patients with IBD in comparison with
healthy controls (HC) and chronic migraine (CM) patients. Although the results showed that
the circulating levels of beta-CGRP in both ulcerative colitis (UC) and Crohn's disease (CD)
patients were significantly lower than those in HC and CM it is neither logical nor reasonable to
reach such conclusions that beta-CGRP has a pathophysiological and protective role in patients
with IBD because this study did not perform any experiments regarding the pathophysiological
and protective role of this neuropeptide.  Apart from this, in the patients cohort, there were 5
CD patients with B2 or B3 and 5 with perianal diseases which cannot be regarded as the first
or initial stages of the disease, therefore,  it is also not appropriate to argue that "this reduction
is not secondary to an established chronic damage of the mucosa, but that could have a key
role in the maintenance of wall homeostasis in the initial IBD stages". However, to observe the
circulating levels of beta-CGRP is a good start to study its role in patients with IBD in terms of
biomarkers or therapeutic target in future.
Please review this paper.
user
Title: Unravelling the role of beta-CGRP in inflammatory bowel disease and its potential role
in gastrointestinal homeostasis
Version: 1 Date: 29 May 2024
Reviewer's report:
This is an observational study dealing with the circulating levels of beta calcitonin gene-
related peptide (beta-CGRP) measured by ELISA in patients with IBD in comparison with
healthy controls (HC) and chronic migraine (CM) patients. Although the results showed that
the circulating levels of beta-CGRP in both ulcerative colitis (UC) and Crohn's disease (CD)
patients were significantly lower than those in HC and CM it is neither logical nor reasonable to
reach such conclusions that beta-CGRP has a pathophysiological and protective role in patients
with IBD because this study did not perform any experiments regarding the pathophysiological
and protective role of this neuropeptide.  Apart from this, in the patients cohort, there were 5
CD patients with B2 or B3 and 5 with perianal diseases which cannot be regarded as the first
or initial stages of the disease, therefore,  it is also not appropriate to argue that "this reduction
is not secondary to an established chronic damage of the mucosa, but that could have a key
role in the maintenance of wall homeostasis in the initial IBD stages". However, to observe the
circulating levels of beta-CGRP is a good start to study its role in patients with IBD in terms of
biomarkers or therapeutic target in future.
assistant